[Thrombolytic therapy of pulmonary artery embolism in early pregnancy with recombinant tissue-type plasminogen activator].
We report on successful thrombolytic treatment of massive pulmonary embolism in a patient in early pregnancy with recombinant tissue-type plasminogen activator (rt-PA). Therapy was started with 20 mg rt-PA intravenously over 20 minutes, followed by two further infusions of 20 mg rt-PA within the next 8 hours. Clinical symptoms and haemodynamic parameters improved 24 hours after initiation of therapy. No bleeding complications were observed and the foetus was not affected. Further thromboembolic episodes could be prevented by anticoagulation with low molecular weight heparin up to full term normal delivery.
Seifried
E
E
Abteilungen Innere Medizin III, Medizinische Universitätsklinik und Poliklinik, Ulm.
Gabelmann
A
A
Ellbrück
D
D
Schmidt
A
A
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy*; D011261:Pregnancy Trimester, First; D011655:Pulmonary Embolism / Q000097:blood / Q000628:therapy*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D006495:Heparin, Low-Molecular-Weight; D011994:Recombinant Proteins; D006493:Heparin; D010959:Tissue Plasminogen Activator
Thrombolytische Therapie einer Lungenarterienembolie in der Frühschwangerschaft mit rekombinantem Gewebe-Plasminogen-Aktivator.